share_log

東陽光長江藥業：截至二零二三年十二月三十一日止年度的年度業績公告

HEC CJ PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 28 06:09
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司（「本公司」）公佈截至2023年12月31日止年度的年度業績。期內，公司錄得營業額人民幣6,294.59百萬元，同比增長68.08%；稅息、折舊及攤銷前溢利達人民幣2,745.44百萬元，增長293.09%；歸屬於公司權益持有人的溢利及全面收益總額為人民幣1,992.62百萬元，較上年度增加2,501.23%。每股基本及攤薄盈利為人民幣2.26元。董事會決定不派發截至2023年12月31日止年度的末期股息。公司及其附屬公司綜合業績按國際財務報告準則編製。公司在抗感染藥和治療慢病藥開發、生產和銷售方面取得顯著進展，並積極推進核心產品在等級醫院及基層醫療市場的推廣。公司將繼續加大藥品開發投入，提升產品研發和創新實力，並完善市場銷售策略。
宜昌東陽光長江藥業股份有限公司（「本公司」）公佈截至2023年12月31日止年度的年度業績。期內，公司錄得營業額人民幣6,294.59百萬元，同比增長68.08%；稅息、折舊及攤銷前溢利達人民幣2,745.44百萬元，增長293.09%；歸屬於公司權益持有人的溢利及全面收益總額為人民幣1,992.62百萬元，較上年度增加2,501.23%。每股基本及攤薄盈利為人民幣2.26元。董事會決定不派發截至2023年12月31日止年度的末期股息。公司及其附屬公司綜合業績按國際財務報告準則編製。公司在抗感染藥和治療慢病藥開發、生產和銷售方面取得顯著進展，並積極推進核心產品在等級醫院及基層醫療市場的推廣。公司將繼續加大藥品開發投入，提升產品研發和創新實力，並完善市場銷售策略。
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (THE “COMPANY”) ANNOUNCES ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023. During the period, the Company recorded revenue of RMB6,294.59 million, a year-on-year increase of 68.08%; profit before tax, depreciation and amortization of RMB2,745.44 million, an increase of 293.09%; the total profit and comprehensive income attributable to equity holders of the Company was RMB1,992.62 million, compared to the previous year 2,501.23% increase. Basic and diluted earnings per share were RMB2.26. The Board of Directors has decided not to distribute the final dividend for the year ended 31 December 2023. The consolidated results of the Company and its subsidiaries are prepared in accordance with international financial reporting criteria. The Company has made significant progress in the development, production and sale of anti-infectious and therapeutic drugs and actively promotes the promotion of its core products in the hospital and primary care markets. The Company will continue to increase its investment in drug development, enhance its R&D and innovation capabilities, and refine its marketing strategy.
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (THE “COMPANY”) ANNOUNCES ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023. During the period, the Company recorded revenue of RMB6,294.59 million, a year-on-year increase of 68.08%; profit before tax, depreciation and amortization of RMB2,745.44 million, an increase of 293.09%; the total profit and comprehensive income attributable to equity holders of the Company was RMB1,992.62 million, compared to the previous year 2,501.23% increase. Basic and diluted earnings per share were RMB2.26. The Board of Directors has decided not to distribute the final dividend for the year ended 31 December 2023. The consolidated results of the Company and its subsidiaries are prepared in accordance with international financial reporting criteria. The Company has made significant progress in the development, production and sale of anti-infectious and therapeutic drugs and actively promotes the promotion of its core products in the hospital and primary care markets. The Company will continue to increase its investment in drug development, enhance its R&D and innovation capabilities, and refine its marketing strategy.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more